Has the threat of waiving COVID-19 vaccine intellectual property rights had its desired effect?
In this final article on the TRIPS waiver for COVID-19 vaccines, medicines, diagnostics and technologies, EPR’s Hannah Balfour considers whether it is the correct strategy to overcome COVID-19 treatment inequalities and explores other options.
In my earlier articles on the proposed Agreement of Trade-Related Intellectual Property Rights (TRIPS) waiver for COVID-19 vaccines, medicines, diagnostics and technologies, I explored the scope of the intellectual property (IP) rights waiver and its potential impacts on pharma, biopharma and biotech, should it be approved. In this last instalment, I focus on the supply of COVID-19 vaccines; discussing whether the IP waiver is the best solution for addressing COVID-19 vaccination disparities, what other strategies are helping to achieve this goal and whether the TRIPS waiver may already have achieved its desired effect.
Access to COVID-19 Tools (ACT) Accelerator, Amnesty International, Association of the British Pharmaceutical Industry (ABPI), AstraZeneca, Biotechnology Innovation Organization (BIO), COVAX, Duke Global Health Innovation Center, European Federation of Pharmaceutical Industries and Associations (EFPIA), International Council of Biotechnology Associations (ICBA), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Janssen, Johnson & Johnson (J&J), Médecins Sans Frontières (MSF), Merck, Pfizer, Pharmaceutical Research and Manufacturers of America (PhRMA), Serum Institute of India (SII), Simon-Kucher & Partners, The World Health Organization (WHO), UNICEF, University of Notre Dame, Vaccines Europe, World Trade Organization (WTO)